Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModuLung: Treosulfan, Pioglitazone, and Clarithromycin vs Nivolumab in NSCLC
NCT02852083Phase 2Unknown
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Jan 2016
- Primary completion
- Jul 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan, pioglitazone, clarithromycin in non-small cell lung cancer (NSCLC), sponsored by Universitätsklinikum Regensburg. Status: unknown.
02
Drugs
treosulfanpioglitazoneclarithromycin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02852083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852083.